Skip to main content

Hyaluronidase / Ocrelizumab Dosage

Medically reviewed by Drugs.com. Last updated on Nov 5, 2024.

Applies to the following strengths: ocsq 23,000 units-920 mg /23 mL

Usual Adult Dose for Multiple Sclerosis

23 mL (920 mg ocrelizumab and 23,000 units hyaluronidase) subcutaneously over approximately 10 minutes every 6 months

Comments:


Uses:

Renal Dose Adjustments

Mild Renal Dysfunction: No adjustment recommended.
Moderate and Severe Renal Dysfunction: Data not available

Liver Dose Adjustments

Mild Liver Dysfunction: No adjustment recommended.
Moderate and Severe Liver Dysfunction: Data not available

Precautions

US FDA requires a medication guide to assure safe use. For additional information go to: www.fda.gov/drugs/drug-safety-and-availability/medication-guides

CONTRAINDICATIONS:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Assessments prior to the first dose:

Premedication:

Storage requirements:

Preparation and administration techniques:

General:

Monitoring:

Patient advice:

More about hyaluronidase / ocrelizumab

Patient resources

Other brands

Ocrevus Zunovo

Professional resources

Other brands

Ocrevus Zunovo

Related treatment guides

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.